Literature DB >> 4563149

Immune responses in vitro. VI. Genetic control of the in vivo-in vitro discrepancies in 19S antibody synthesis.

R E Click, L Benck, B J Alter, J C Lovchik.   

Abstract

The finding that the relationship of the in vitro and in vivo responses of different strains of mice is under genetic control indicates that at least two mechanisms must operate under in vivo conditions to control 19S antibody synthesis. One is involved in the termination of 19S antibody synthesis; the other has a regulatory role on the magnitude of the response. In light of these findings, various concepts based on other genetically controlled immune responses and on the limiting dilution technique should be reassessed. Furthermore, the suppressive in vivo mechanism may be an important type of control in the resistance or susceptibility to the establishment or maintainance of neoplasms.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4563149      PMCID: PMC2139308          DOI: 10.1084/jem.136.5.1241

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  35 in total

1.  A THREE-CELL INTERACTION REQUIRED FOR THE INDUCTION OF THE PRIMARY IMMUNE RESPONSE in vitro.

Authors:  D E Mosier; L W Coppleson
Journal:  Proc Natl Acad Sci U S A       Date:  1968-10       Impact factor: 11.205

2.  Genetic control of immune response to theta-AKR alloantigen.

Authors:  H Fuji; M Zaleski; F Milgrom
Journal:  J Immunol       Date:  1972-01       Impact factor: 5.422

3.  Primary immune response in cultures of spleen cells.

Authors:  J Marbrook
Journal:  Lancet       Date:  1967-12-16       Impact factor: 79.321

4.  The genetics of the immune response.

Authors:  E S Lennox
Journal:  Proc R Soc Lond B Biol Sci       Date:  1966-11-22

5.  Genetic control of the antibody response to a synthetic polypeptide: transfer of response with spleen cells or lymphoid precursors.

Authors:  M L Tyan; H O McDevitt; L A Herzenberg
Journal:  Transplant Proc       Date:  1969-03       Impact factor: 1.066

Review 6.  Regulatory effect of antibody on the immune response.

Authors:  J W Uhr; G Möller
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

7.  Conversion of non-immune rabbit spleen cells by ribonucleic acid of lymphoid cells from an immunized rabbit to produce IgM and IgG antibody of foreign heavy-chain allotype.

Authors:  C Bell; S Dray
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

8.  Genetic control of susceptibility to Friend leukemia virus in mice: studies with the spleen focus assay method.

Authors:  A Axelrad
Journal:  Natl Cancer Inst Monogr       Date:  1966-09

9.  Induction of a hemolysin response in vitro. Interaction of cells of bone marrow origin and thymic origin.

Authors:  K U Hartmann
Journal:  J Exp Med       Date:  1970-12-01       Impact factor: 14.307

10.  IMMUNOGLOBULIN ISOANTIGENS (ALLOTYPES) IN THE MOUSE. I. GENETICS AND CROSS-REACTIONS OF THE 7S GAMMA-2A-ISOANTIGENS CONTROLLED BY ALLELES AT THE IG-1 LOCUS.

Authors:  L A HERZENBERG; N L WARNER; L A HERZENBERG
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

View more
  4 in total

1.  Promotion of replication in lymphoid cells by specific thiols and disulfides in vitro. Effects on mouse lymphoma cells in comparison with splenic lymphocytes.

Authors:  J D Broome; M W Jeng
Journal:  J Exp Med       Date:  1973-09-01       Impact factor: 14.307

2.  Genetic control of T-cell subset representation in inbred mice.

Authors:  G Kraal; I L Weissman; E C Butcher
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

3.  Conversion of immune response patterns from high to low and low to high by an RNase-sensitive thymocyte extract.

Authors:  K Nakamura
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

Review 4.  A review: alteration of in vitro reproduction processes by thiols -emphasis on 2-mercaptoethanol.

Authors:  Robert E Click
Journal:  J Reprod Dev       Date:  2014-08-04       Impact factor: 2.214

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.